Failure to prevent the release of unsuitable blood and blood components for further manufacturing.
Inspection Record
BioLife Plasma Services L.P. — FDA 483 Findings
Inspectors Shelley H BeausoleilThe inspectors who signed the published document.Inspector lookup
View the regulator's official source The source document is always the basis for judgement.
Findings
Failure to determine the eligibility of a donor of blood or blood components before collection.
The responsible physician improperly delegated activities related to the collection of blood and blood components.
Failure to make reasonable attempts to notify a donor who has been determined not be to eligible as a donor based on eligibility criteria.
The standard operating procedure fails to include written descriptions of methods for performing donor qualifying tests and measurements, including minimum and maximum values for a test or procedure whena factor in determining acceptability.
A record as of the US FDA document published on 2026-10-20. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.